RT Journal Article
SR Electronic
T1 A First Analysis of Excess Mortality in Switzerland in 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.14.21253551
DO 10.1101/2021.03.14.21253551
A1 Locatelli, Isabella
A1 Rousson, Valentin
YR 2021
UL http://medrxiv.org/content/early/2021/03/17/2021.03.14.21253551.abstract
AB Objective To quantify the excess all-cause mortality in Switzerland in 2020, a key indicator for assessing direct and indirect consequences of the COVID-19 pandemic.Methods Using official data on deaths in Switzerland, all-cause mortality in 2020 was compared with that of previous years using directly standardized mortality rates, age- and sex-specific mortality rates, and life expectancy.Results The standardized mortality rate was 8.6% higher in 2020 than in 2019, returning to the level observed 5-6 years ago. This increase was greater for men (10.4%) than for women (7.0%), and was statistically significant only for men over 70 years of age, and for women over 75 years of age. The decrease in life expectancy in 2020 compared to 2019 was about 1%, with a loss of 9.4 months for men and 5.1 months for women.Conclusions There was an excess mortality in Switzerland in 2020, linked to the COVID-19 pandemic. However, as this excess only concerned the elderly, the resulting loss of life expectancy was restricted to a few months.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are publicy available